In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1303-1310

  Usui, Toru ^a,b   Hashizume, Takanori ^a   Katsumata, Takashi ^a   Yokoi, Tsuyoshi ^b   Komuro, Setsuko ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 3A; GLUTATHIONE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; RECOMBINANT ENZYME; ROSIGLITAZONE; TROGLITAZONE;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME DEFECT; ENZYME DEFICIENCY; GENE MUTATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER INJURY; LIVER MICROSOME; LIVER TOXICITY; NULL ALLELE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; WILD TYPE;

CELLS, CULTURED; CHROMANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENOTYPE; GLUTATHIONE TRANSFERASE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; MICROSOMES, LIVER; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES;

EID: 79959453202     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038661     Document Type: Article

References (36)

1. Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J, Winkler L, and Oesch F (1996) A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 236:184-186. (Pubitemid 26100747)
2. Bae MA and Song BJ (2003) Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 63:401-408.
3. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, et al. (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41:816-819.
4. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16. (Pubitemid 38134055)
5. Fujiwara T, Okuno A, Yoshioka S, and Horikoshi H (1995) Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 44:486-490.
6. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, and Gasser R (2001a) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
7. Funk C, Ponelle C, Scheuermann G, and Pantze M (2001b) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627-635. (Pubitemid 32179943)
8. Gitlin N, Julie NL, Spurr CL, Lim KN, and Juarbe HM (1998) Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36-38. (Pubitemid 28304650)
9. Hayes JD, Flanagan JU, and Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-88. (Pubitemid 40261798)
10. He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, and Woolf TF (2004) Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab Dispos 32:639-646. (Pubitemid 38668157)
11. Hewitt NJ, Lloyd S, Hayden M, Butler R, Sakai Y, Springer R, Fackett A, and Li AP (2002) Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chem Biol Interact 142:73-82.
12. Hosomi H, Akai S, Minami K, Yoshikawa Y, Fukami T, Nakajima M, and Yokoi T (2010) An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and γ-glutamylcysteine synthetase knockdown cells. Toxicol In Vitro 24:1032-1038.
13. Hosomi H, Fukami T, Iwamura A, Nakajima M, and Yokoi T (2011) Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab Dispos doi:10.1124/dmd.110.037077.
14. Isley WL (2003) Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2:581-586.
15. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, and Baillie TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62-70.
16. Lim PL, Liu J, Go ML, and Boelsterli UA (2008) The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 101:341-349.
17. Masubuchi Y, Kano S, and Horie T (2006) Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222:233-239.
18. Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, and Okazaki O (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970-1977.
19. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, and Tamai I (2004) Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 32:291-294. (Pubitemid 38263886)
20. Obach RS, Kalgutkar AS, Soglia JR, and Zhao SX (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 21:1814-1822.
21. Russmann S, Jetter A, and Kullak-Ublick GA (2010) Pharmacogenetics of drug-induced liver injury. Hepatology 52:748-761.
22. Saha S, New LS, Ho HK, Chui WK, and Chan EC (2010) Direct toxicity effects of sulfoconjugated troglitazone on human hepatocytes. Toxicol Lett 195:135-141.
23. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, and Chen CS (2005) Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ. Cancer Res 65:1561-1569. (Pubitemid 40270186)
24. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, and Takeuchi H (1998) An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 21:2140-2143. (Pubitemid 28549164)
25. Sigrist S, Bedoucha M, and Boelsterli UA (2000) Down-regulation by troglitazone of hepatic tumor necrosis factor-α and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem Pharmacol 60:67-75. (Pubitemid 30243086)
26. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, and Jaillon P (2000) Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 67:432-437. (Pubitemid 30246823)
27. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, and Paulding CA (2010) A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42:711-714.
28. Sparano N and Seaton TL (1998) Troglitazone in type II diabetes mellitus. Pharmacotherapy 18:539-548. (Pubitemid 28228337)
29. Tettey JN, Maggs JL, Rapeport WG, Pirmohamed M, and Park BK (2001) Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol 14:965-974. (Pubitemid 32800152)
30. Ueda K, Ishitsu T, Seo T, Ueda N, Murata T, Hori M, and Nakagawa K (2007) Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 8:435-442. (Pubitemid 46746351)
31. Uetrecht J (2009) Immune-mediated adverse drug reactions. Chem Res Toxicol 22:24-34.
32. Usui T, Mise M, Hashizume T, Yabuki M, and Komuro S (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:2383-2392.
33. Walgren JL, Mitchell MD, and Thompson DC (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35:325-361. (Pubitemid 40691298)
34. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, Takahashi T, Miyoshi K, Nakamura K, Izumi T, et al. (2003) A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73:435-455. (Pubitemid 36549828)
35. Watanabe T, Ohashi Y, Yasuda M, Takaoka M, Furukawa T, Yamato T, Sanbuissho A, and Manabe S (1999) Was it possible to predict liver dysfunction caused by troglitazone during the nonclinical safety studies? Iyakuhin Kenkyu 30:537-546.
36. Yamamoto Y, Yamazaki H, Ikeda T, Watanabe T, Iwabuchi H, Nakajima M, and Yokoi T (2002) Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab Dispos 30:155-160. (Pubitemid 34106533)